At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 66 enrolled
Drug / intervention
Zanubrutinib +1 moredrug
Likely dose
Zanubrutinib 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
In Brief
A Phase 1 clinical trial evaluating Zanubrutinib and Lenalidomide for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Completed, enrolled 66 participants across 10 sites.
Detailed Summary
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartSep 2020
Primary CompletionMar 2024
TodayJul 2026
First PostedJun 17, 2020
Enrollment StartSep 11, 2020
Primary CompletionMar 28, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.0 years ago
Interventions
Zanubrutinibdrug
160 mg administered orally twice daily (BID)
Lenalidomidedrug
Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval.